Market›Health Care›Biotechnology›Biotechnology
ARMATA PHARMACEUTICA

ARMP

$12.92Apr 26, 2021 – Apr 24, 2026
Health CareBiotechnology$437M
MVM
-$2.3M
TD Variance
-8.730

Every news event mapped to its market reaction — 133 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2025-10-22+104.5%newsSeeking AlphaArmata surges on mid-stage trial data for antibacterial agent
2025-10-22+104.5%newsSeeking AlphaArmata surges on mid-stage trial data for antibacterial agent - Seeking Alpha
2025-10-22+104.5%newsInvesting.com South AfricaArmata stock soars after positive Phase 2a bacteriophage trial results By Investing.com - Investing.com South Africa
2025-10-22+104.5%newsGuruFocusArmata Pharmaceuticals (ARMP) Shares Surge by 19% - GuruFocus
2025-10-22+104.5%newsGuruFocusArmata Pharmaceuticals (ARMP) Prepares for Phase 3 Trial Followi - GuruFocus
2025-10-22+104.5%newsGuruFocusArmata Pharmaceuticals (ARMP) Reports Promising Phase 2a Trial R - GuruFocus
2025-05-19+66.9%analystGuruFocusArmata Pharmaceuticals (ARMP) Price Target Boosted Following Cli - GuruFocus
2025-05-19+66.9%newsGuruFocusArmata Pharmaceuticals Announces Positive Topline Data from the - GuruFocus
2026-02-23+36.2%legalMT NewswiresArmata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment
2026-02-23+36.2%legalPR NewswireArmata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
2026-02-23+36.2%legalPR NewswireArmata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 - PR Newswire
2026-02-23+36.2%analystGuruFocusARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus
2021-10-29+30.0%legalSEC EDGARARMP 8-K: 1.01, 3.02, 8.01 (SEC Filing)
2023-01-10+27.6%legalSEC EDGARARMP 8-K: 1.01, 2.03, 3.02 (SEC Filing)
2025-12-01-27.3%legalSEC EDGARARMP 8-K: 1.01 and (SEC Filing)
2023-11-15-25.3%earningsGuruFocusArmata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Resu - GuruFocus
2022-03-17+22.0%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.23 beats by $0.05, revenue of $0.99M
2023-08-22-17.7%newsYahoo FinanceArmata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why - Yahoo Finance
2026-04-06+16.9%newsXã Vĩnh CôngIs Armata (ARMP) Stock Ready to Rally | Price at $11.82, Up 16.16% - Money Flow - Xã Vĩnh Công
2022-01-05+15.7%legalSEC EDGARARMP 8-K: 7.01, 8.01 (SEC Filing)
2024-11-15-15.5%legalSEC EDGARARMP 8-K: 1.01, 5.02 (SEC Filing)
2025-10-23-15.5%newsYahoo FinanceArmata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - Yahoo Finance
2025-10-23-15.5%newssimplywall.stA Look at Armata Pharmaceuticals’s Valuation After Positive Phase 2a Bacteriophage Trial Results (ARMP) - simplywall.st
2026-03-25+15.1%newsPR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
2026-03-25+15.1%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2026-03-25+15.1%newsPR NewswireArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results - PR Newswire
2023-05-05-14.9%legalSEC EDGARARMP 8-K: 5.02 (SEC Filing)
2023-11-14-14.8%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.86, revenue of $1.2M
2023-11-14-14.8%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2023-03-16+14.3%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.29 misses by $0.01, revenue of $1.05M misses by $0.62M
2023-03-16+14.3%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2026-01-13-14.0%newsStock TitanAntibiotic-resistant Staphylococcus aureus study moves to Armata Phase 3 - Stock Titan
2026-01-13-14.0%newsStock TitanFirst phage therapy for staph bloodstream infections heads to Phase 3 - Stock Titan
2024-08-14-12.0%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.25
2025-05-01-11.6%legalSEC EDGARARMP 8-K: 8.01 and (SEC Filing)
2022-11-07+11.6%newsGuruFocusJulian P. Kirk Net Worth (2026) - GuruFocus
2022-11-09-11.6%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.24 beats by $0.04, revenue of $1.34M misses by $0.32M
2022-11-09-11.6%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2022-12-19-11.3%legalSEC EDGARARMP 8-K: 5.02 and (SEC Filing)
2025-11-13+11.1%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.74, revenue of $1.16M
2022-09-20+11.1%legalSEC EDGARARMP 8-K: 2.02, 8.01 (SEC Filing)
2021-11-10-10.0%earningsSeeking AlphaArmata Pharmaceuticals EPS beats by $0.04, beats on revenue
2025-03-21-10.0%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.23, revenue of $1.2M
2025-03-21-10.0%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2025-03-21-10.0%earningsqz.comArmata Pharmaceuticals Inc. (ARMP) reports earnings - qz.com
2026-02-24+9.8%analystInvesting.comH.C. Wainwright lowers Armata Pharmaceuticals stock price target to $15 - Investing.com
2024-05-07+9.8%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.69 misses by $0.38, revenue of $0.97M misses by $0.17M
2024-05-07+9.8%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2026-03-13-9.3%earningsSeeking AlphaSmall-Cap healthcare stocks ranked by quant ratings after earnings season
2025-11-18+9.2%newsPR NewswireArmata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - PR Newswire
2026-04-22-9.2%earningsXã Châu ThànhARMP (Armata Pharmaceuticals Inc.) Q4 2025 EPS drastically misses analyst estimates, sending its shares down 6.37% today. - Revenue Growth - Xã Châu Thành
2026-01-26+8.9%legalSEC EDGARARMP 8-K: 1.01 and (SEC Filing)
2026-04-09-8.8%earningsIntellectia AIARMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
2021-06-14-8.8%legalSEC EDGARARMP 8-K: 5.07 and 8.01 (SEC Filing)
2023-02-24+8.2%newsGuruFocusJoseph M Patti Net Worth (2026) - GuruFocus
2024-08-15-8.1%legalSEC EDGARARMP 8-K: 5.02 and (SEC Filing)
2026-04-23-7.5%earningsCổng thông tin điện tử Tỉnh Sơn LaARMP (Armata Pharmaceuticals Inc.) Q4 2025 EPS drastically misses analyst estimates, sending its shares down 6.37% today. - Geographic Trends - Cổng thông tin điện tử Tỉnh Sơn La
2026-04-23-7.5%earningsUBND thành phố Hải PhòngARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors. - Retail Trader Ideas - UBND thành phố Hải Phòng
2026-04-23-7.5%earningsXã Thanh HàARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors. - Cost Structure - Xã Thanh Hà
2024-03-06-7.3%newsCNNsymbol__ Stock Quote Price and Forecast - CNN
2023-05-11-7.1%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.40, revenue of $0.79M
2024-08-13-7.1%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2026-03-05-6.8%newsStocktwitsArmata Pharmaceuticals Stock Soars To Record High After Phage Therapy Data In Deadly Infection Trial; Retail Traders Pile In - Stocktwits
2022-02-09+6.6%newsSeeking AlphaArmata Pharmaceuticals announces $45M investment by Innoviva
2024-09-26+6.5%legalSEC EDGARARMP 8-K: 5.02 (SEC Filing)
2026-03-02+6.4%legalInsider MonkeyH.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
2026-03-02+6.4%legalYahoo FinanceH.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod - Yahoo Finance
2026-03-12-6.3%newsSeeking AlphaArmata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags
2026-03-12-6.3%newsSeeking AlphaArmata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags - Seeking Alpha
2024-03-04-6.3%expansionSeeking AlphaArmata enters $35M credit agreement with Innoviva
2024-03-04-6.3%legalSEC EDGARARMP 8-K: 1.01, 2.03 (SEC Filing)
2025-03-12+6.2%expansionSeeking AlphaArmata Pharmaceuticals announces $10M secured credit agreement with Innoviva
2025-03-12+6.2%legalSEC EDGARARMP 8-K: 1.01, 2.03, 7.01 (SEC Filing)
2023-06-27-5.8%legalSEC EDGARARMP 8-K: 2.02, 8.01 (SEC Filing)
2024-03-21+5.5%earningsSeeking AlphaArmata Pharmaceuticals reports Q4 results
2024-03-21+5.5%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2023-07-19+4.8%legalSEC EDGARARMP 8-K: 5.02 and (SEC Filing)
2025-04-24+4.7%newsStock TitanARMP Stock Price, News & Analysis - Stock Titan
2025-08-12+4.5%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.45, revenue of $2.17M
2025-08-12+4.5%legalSEC EDGARARMP 8-K: 1.01, 2.02, 2.03, 7.01 (SEC Filing)
2025-08-12+4.5%legalPR NewswireArmata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update - PR Newswire
2023-05-12+4.4%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2021-11-18+4.4%legalSeeking AlphaArmata Pharma up 8% on FDA acceptance of IND application for antibiotic
2025-04-02-4.0%legalSEC EDGARARMP 8-K: 8.01 (SEC Filing)
2025-11-12-3.9%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2025-11-12-3.9%newsPR NewswireArmata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PR Newswire
2025-11-12-3.9%earningsYahoo FinanceArmata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
2024-05-11+3.9%earningsMarketBeatArmata Pharmaceuticals (ARMP) Stock Forecast and Price Target 2026 - MarketBeat
2021-11-02-3.8%legalSEC EDGARARMP 8-K: 1.01, 8.01 (SEC Filing)
2022-05-12-3.8%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.30 misses by $0.09, revenue of $1.24M beats by $0.26M
2025-05-24+3.7%newsIntellectia AIARMP Forecast — Price Prediction for 2026. Should I Buy ARMP? - Intellectia AI
2023-09-20-3.5%legalSEC EDGARARMP 8-K: 5.02 and 5.07 (SEC Filing)
2022-03-31-3.4%legalSEC EDGARARMP 8-K: 3.02, 5.07, 8.01 (SEC Filing)
2025-05-15-3.3%newsIntellectia AIARMP Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
2026-04-03+3.2%newsThe Globe and MailArmata Pharmaceuticals Sets Timeline for 2026 Annual Meeting - The Globe and Mail
2025-09-01+2.7%newsYahoo FinanceIs Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
2024-10-03+2.7%legalSEC EDGARARMP 8-K: 5.02 and (SEC Filing)
2021-08-13-2.5%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2023-03-06-2.2%newsSeeking AlphaArmata surges 15% as inhaled bacterial infection drug shows promise in lung disorder patients
2021-08-12-2.0%earningsSeeking AlphaArmata Pharmaceuticals EPS beats by $0.02, beats on revenue
2025-05-14-2.0%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.20 beats by $0.18, revenue of $0.49M misses by $0.89M
2025-05-14-2.0%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2024-11-13-2.0%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.15 beats by $0.13
2024-11-13-2.0%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2022-11-28+1.8%newsGuruFocusTodd Patrick Net Worth (2026) - GuruFocus
2022-08-11-1.5%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.26, revenue of $1.88M
2022-08-11-1.5%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2022-03-28+1.3%legalSEC EDGARARMP 8-K: 5.02 and (SEC Filing)
2024-07-25-1.3%legalSEC EDGARARMP 8-K: 5.02 and (SEC Filing)
2022-08-01+1.2%legalSeeking AlphaFDA clears Armata Pharma's application for its treatment for prosthetic joint infection
2021-08-02+1.0%earningsSeeking AlphaArmata Pharma CEO steps down
2024-12-04+0.9%legalSEC EDGARARMP 8-K: 5.02 and (SEC Filing)
2021-08-04+0.9%legalSEC EDGARARMP 8-K: 5.02 (SEC Filing)
2022-08-15+0.8%analystZacks Investment ResearchWhat is the current Price Target and Forecast for Armata Pharmaceuticals (ARMP) - Zacks Investment Research
2021-05-14+0.8%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2022-09-01+0.7%analystTradingViewARMP Forecast — Price Target — Prediction for 2027 - TradingView
2026-03-26+0.7%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$3.42, revenue of $1.1M
2026-03-26+0.7%earningsInvesting.comArmata Pharmaceuticals stock edges down on fourth quarter earnings miss - Investing.com
2026-03-26+0.7%earningsBayelsa WatchArmata Pharmaceuticals (ARMP) Q4 and Full-Year 2025 Earnings: Revenue Beat, Net Loss Hits $173.8M - Bayelsa Watch
2026-04-02-0.7%legalSEC EDGARARMP 8-K: 8.01 (SEC Filing)
2026-04-02-0.7%newsInvesting.comArmata Pharmaceuticals schedules annual meeting for June 11 - Investing.com
2025-10-06+0.7%newsYahoo FinanceAre Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Yahoo Finance
2022-02-11-0.6%legalSEC EDGARARMP 8-K: 1.01, 3.02, 8.01 (SEC Filing)
2023-08-14-0.5%earningsSeeking AlphaArmata Pharmaceuticals GAAP EPS of -$0.17, revenue of $0.98M
2023-08-14-0.5%legalSEC EDGARARMP 8-K: 2.02 and (SEC Filing)
2023-07-11+0.3%executiveSeeking AlphaArmata Pharmaceuticals gets $25M in financing and new executive chief
2023-07-11+0.3%legalSEC EDGARARMP 8-K: 1.01, 2.03, 5.02, 8.01 (SEC Filing)
2026-03-19+0.2%newsPR NewswireArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
2026-03-19+0.2%newsPR NewswireArmata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update - PR Newswire
2026-03-19+0.2%earningsStock TitanArmata pushes back earnings as FDA backs Phase 3 staph blood infection study - Stock Titan
2026-03-19+0.2%newsGuruFocusArmata Pharmaceuticals (ARMP) Delays Financial Results Release - GuruFocus
2026-03-19+0.2%newsTradingViewArmata Pharmaceuticals delays 2025 results, wins QIDP and readies Phase 3 for AP-SA02 - TradingView
2026-04-24—analystMSNArmata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
tickerdossier.comtickerdossier.substack.com